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ABSTRACT

REGULATION OF LKB1-STRAD-MO25 COMPLEX EXPRESSION AND
ACTIVATION OF AMPK IN SKELETAL MUSCLE BY THYROID HORMONE

Devon J. Branvold
Department of Physiology and Developmental Biology
Master of Science

AMP-activated protein kinase (AMPK), a heterotrimeric protein which serves as
a metabolic master switch in skeletal muscle, is a research target for the pharmaceutical
treatment and prevention of type 2 diabetes. The expression of all of the isoforms of the
subunits of AMPK and AMPK activity are increased in skeletal muscle tissue of
hyperthyroid rats. Activity of AMPK is regulated by an upstream kinase (AMPKK). The
LKB1-STRAD-MO25 complex is a major AMPKK in skeletal muscle. This experiment
was designed to determine whether the increase in AMPK activity is accompanied by a
thyroid hormone-induced increase in the expression of the LKB1-STRAD-MO25
complex. LKB1-STRAD-MO25 complex protein expression was determined by Western
blots in control rats, in rats given 3 mg of thyroxine and 1 mg of triiodothyronine per
kilogram chow for 4 weeks, and in rats given 0.01% propylthiouracil (PTU) in drinking
water for 4 weeks. The relative expression of LKB1, MO25, and STRAD, as well as
PGC-1α, increased in the soleus of thyroid hormone treated rats vs. the controls. MO25
mRNA increased with thyroid hormone treatment, and STRAD mRNA increased with

PTU treatment. Phospho-AMPK and phospho-ACC increased in response to electrical
stimulation in muscles of all treatment groups, but was most markedly increased in
hyperthyroid rats. Thyroid hormone treatment also increased the amount of phosphoCREB in the soleus, heart, and red quadriceps. These data provide evidence that thyroid
hormone partially controls expression of the LKB1-STRAD-MO25 complex, as well the
subsequent activation of AMPK.
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PROSPECTUS
Introduction
AMP-activated protein kinase (AMPK), a heterotrimeric protein which serves as
a metabolic master switch in skeletal muscle, is a research target for the pharmaceutical
treatment and prevention of type 2 diabetes. AMPK has been shown to have
involvement in fatty acid oxidation, glucose uptake, and increase of citric acid cycle and
electron transport chain enzymes. Many of the effects of thyroid hormone in skeletal
muscle are similar, including increases in electron transport chain and citric acid cycle
enzymes, enzymes involved in ketone oxidation, hexokinase and GLUT-4. In 2002 it
was shown that treatment with thyroid hormone results in increased expression of all of
the isoforms of the subunits of AMPK (1). AMPK activity was also shown to increase in
the skeletal muscle tissue of thyroid hormone-treated rats. Activity of AMPK is
regulated by an upstream AMPK kinase (AMPKK). The LKB1-STRAD-MO25 complex
has been shown to be a major AMPKK in skeletal muscle. This experiment was
designed to determine whether the increase in AMPK activity is due to a thyroid
hormone-induced increase in the expression of the LKB1-STRAD-MO25 complex.

About 5’-AMP-activated protein kinase.
5’-AMP-activated protein kinase (AMPK) acts as a fuel gauge for the cell,
responding to changes in cellular energy (2). When it “senses” low ATP, it turns off
ATP-depleting pathways and switches on mechanisms of ATP production (2). AMPK is
a heterotrimer consisting of a 63-kD alpha subunit, a 40-kDbeta subunit, and a 38-kD
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gamma subunit (3). There are at least two isoforms of the alpha and beta subunits, and
three isoforms of the gamma subunit.
The alpha subunit contains the site of phosphorylation by AMPKK, as well as the
catalytic site for kinase activity (4, 5). The two alpha subunits differ somewhat in
expression and function. Alpha1 is widely expressed throughout the body, whereas
alpha2 expression is highly concentrated in cardiac and skeletal muscle and in the liver
(4, 6). Alpha2 is stimulated to a much higher extent than alpha1 by 5’-AMP, and
reactivation of the AMPK complex by AMPKK is stimulated by AMP to a much larger
extent for the alpha2 complex (4). Both are activated by the same upstream kinase, and
inactivated by PP2C and PP2A, but alpha2 is dephosphorylated much more readily by
PP2A (4). Alpha1 is mainly cytosolic, whereas alpha2, although also expressed in the
cytosol, is highly expressed throughout the nucleus, except in the nucleolus (4).
The beta subunit contains a highly conserved ASC domain used for protein
binding (7). Some evidence shows that the beta subunit acts as a scaffold between the
alpha and gamma subunits, but a recent study provided evidence that the beta and
gamma subunits both bind to the alpha subunits, but not to each other (8). The beta1
subunit is predominantly expressed in the liver, but in skeletal muscle, beta1 and beta2
are expressed in fast twitch muscles and beta1 only is expressed in slow twitch muscles
(9). The beta subunit contains a glycogen binding domain, and it seems that this
association gives AMPK access to glycogen synthase and glycogen phosphatase, two
enzymes with which AMPK co-immunoprecipitates (10).
The gamma subunit has three isoforms, which differ significantly in
expression (11). The gamma1 subunit is much more highly expressed than the other two
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in most tissues, except in the brain and testis, where all three seem to have nearly equal
expression (11). Both gamma1 and gamma2 subunits are expressed in various tissues,
whereas gamma3 seems restricted to skeletal muscle (11). All three readily complex
with the alpha subunit without preference, but gamma1 is more often formed because it
is much more prevalent (11). The gamma2 subunit is significantly more AMP-dependent
than the other two isoforms (11). The gamma subunit contains four repeats of a protein
module called cystathionine beta-synthase (CBS), which have a regulatory function (12).
AMP binds to a set of two CBS domains (13), also called a “Bateman domain (14).” One
model suggests that AMP binds to the CBS domain of the gamma subunit, stabilizing
interaction between the alpha and gamma subunit, which opens up the autoinhibitory
region of the alpha subunit, allowing the Thr172 site to be exposed and phosphorylated
(11).

AMPK Activation
AMPK is activated during times of cellular stress, such as exercise, ischemia, and
hypoxia (15). AMPK senses increases in the AMP/ATP ratio and the creatine/creatine
phosphate ratio (15). AMPK is allosterically activated by AMP, and inhibited by CP and
ATP (16), which allows for its sensitivity to cellular energy. ATP inhibits AMPK by
binding to an allosteric site (5). AMP is reported to activate AMPK via three distinct
pathways. The first pathway involves allosteric activation of AMP via binding to the
gamma subunit (5, 16). AMP, when bound to the gamma subunit, also makes AMPK a
poor substrate for protein phosphatase 2C (16, 17). The third pathway, that AMPbinding makes AMPK a better substrate for its upstream kinase, AMPKK, is currently in
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dispute. Hardie et al (5), using partially purified AMPKK, reported that AMP allowed
for increased phosphorylation of AMPK by its kinase. Carling et al (17, 18) reported that
when using purified LKB1, the catalytic protein in the LKB1-STRAD-MO25 complex, a
known AMPKK, AMP does not directly activate LKB1. AMP, also reportedly, does not
promote phosphorylation of AMPK by CAMKK beta, another known AMPKK (17, 19,
20). Carling proposes that the results would be the same for LKB1, since both
phosphorylate the same residue on AMPK (17). Carling suggests that protein
phosphatase 2C in the imperfectly purified AMPKK is responsible for the results
Hardie’s lab observed (17). Whether Hardie’s partially purified AMPKK or Suter’s and
Carling’s recombinant LKB1 and AMPK, purified from bacteria (18), are indicative of
what really occurs in mammalian cells will have to be delineated by further research.
In 2003, LKB1, STRAD, and MO25 were shown to be an upstream kinase for
AMPK, with LKB1 in possession of the catalytic domain (21, 22). LKB1 is a
serine/threonine kinase, which has been shown to be a tumor suppressor (21, 23).
Mutations in LKB1 are linked to Peutz-Jeghers syndrome, in which multiple
gastrointestinal polyps form and the likelihood of malignant tumors is greatly increased
(24). LKB1 alone is mainly localized in the nucleus, but when associated with STRAD
and MO25, it is anchored in the cytoplasm (21). STRAD and MO25 have no catalytic
function (21). Association between LKB1 and STRAD is enhanced by increasing levels
of MO25 in a dose-dependent fashion. Optimal activation of AMPK by LKB1 requires
the presence of all three proteins (21, 25).
For over a decade it has been known that calmodulin-dependent protein kinase
kinase-beta (CaMKKbeta) can phosphorylate and thereby activate AMPK, but it was not
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the main AMPKK in liver (26). Richter et al (27) found that CaMKK inhibitors strongly
inhibited AMPK phosphorylation in mouse soleus and EDL muscles after 2 minutes of
contraction, but much less as time of contraction increased. CaMKK inhibitors had no
effect on 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR)
phosphorylation and activation of AMPK (27). AICAR is taken into the cell and
converted to ZMP, an AMP analog that has been shown to activate AMPK (28). Recent
LKB1 knockout studies have shown that without LKB1, electrical and AICAR
stimulation of muscle results in very little phosphorylation of AMPK and of ACC,
providing evidence that LKB1-STRAD-MO25 is the major AMPKK in muscle (29).

AMPK and Lipid Metabolism
One of the effects of exercise is an increase in fatty acid metabolism, which
provides more energy for the cell. One of the key pathways in AMPK’s regulation of
fatty acid oxidation is the phosphorylation and inactivation of acetyl-CoA carboxylase
(30). Acetyl-CoA carboxylase (ACC) converts acetyl-CoA to malonyl-CoA, an inhibitor
of carnitine parmitoyltransferase 1 (CPT-1). CPT-1 transports fatty acids into the
mitochondria for oxidation. Inactivation of ACC, therefore, results in increased fatty
acid transport and subsequent oxidation. It is also thought that the decrease in malonylCoA occurs as a result of malonyl-CoA decarboxylase (MCD), which may be regulated
by AMPK (31). MCD is an antagonist to ACC, decarboxylating malonyl-CoA to acetylCoA, resulting in decreased malonyl-CoA and increased CPT-1 and fatty acid oxidation.
AMPK also plays an important role in lipid metabolism in the liver. It has long
been known that hepatic ACC has been regulated in the liver by phosphorylation (32).
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AMPK also phosphorylates and inactivates 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGR), a key enzyme in cholesterol synthesis (28). HMGR converts 3-hydroxy-3methylglutaryl-CoA, which is made from acetyl-CoA, into mevalonic acid, which then
travels down several more metabolic steps to become cholesterol. AMPK, therefore,
helps regulate fatty acid oxidation and cholesterol synthesis.

AMPK and Glucose Transport
Insulin is a hormone which helps regulate glucose levels in the body. When
blood glucose is high, insulin is released from the Islets of Langerhans. Insulin, among
other things, will then facilitate the uptake of glucose into cells via increased expression
and translocation of glucose transporter GLUT-4 (34). Under conditions of exercise,
however, blood sugar levels are not necessarily high, and insulin concentration
decreases, yet muscles are still able to bring in glucose. AMPK seems to be responsible
in part for this exercise-induced glucose uptake. Goodyear et al. (33) observed that with
exercise, the concentration of GLUT-4 was increased in the plasma membrane, but
decreased in the microsomal membranes, suggesting that exercise facilitates the
translocation of vesicular GLUT-4 to the plasma membrane. While acute exercise
increases GLUT-4 translocation, endurance training will increase the total amount of
GLUT-4 protein available (35). It has been shown that both electrical stimulation and
AICAR treatment increase AMPK activation, glucose uptake, and GLUT-4 translocation
in perfused rat hindlimb muscle, linking exercise-induced glucose uptake to AMPK (36,
37, 38). Chronic AICAR injections, simulating some of the effects of endurance training,
also increase the total amount of GLUT-4 protein in the muscle cell (39).
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Two proteins are essential for the regulation of GLUT-4 expression at a
transcriptional level – myocyte enhancer factor 2 (MEF2) and GLUT-4 enhancer factor
(GEF). Mutations in the DNA binding regions for either of these proteins results in
ablation of transgene GLUT-4 expression (40, 41). These results prompted a study in
2005 which showed that AMPK directly phosphorylates GEF, but it doesn’t seem to
directly activate MEF2 (42). AICAR treatment has been shown, however, to increase
transport of both proteins into the nucleus, as well as increase the binding of both to the
GLUT-4 promoter region (42).
There is another protein involved in carbohydrate metabolism that is worthy of
mention along with GLUT-4. The enzyme hexokinase phosphorylates a six-carbon
sugar, most notably glucose, which is the first step in glycolysis. When glucose is
transported into the cell it is phosphorylated by hexokinase. This phosphorylation keeps
glucose from leaving the cell, and by changing the structure of glucose through
phosphorylation, it decreases the concentration of glucose molecules, allowing a
gradient for more glucose to be transported into the cell. Hexokinase II transcription is
increased in both red and white skeletal muscle upon treatment with AICAR (43). With
chronic injections of AICAR, total protein content of hexokinase II increases in rat
skeletal muscle (44).

AMPK and Mitochondria
Mitochondria are often called the powerhouse of the cell. After pyruvate is
formed from glucose during glycolysis in the cytoplasm, it is transported into the
mitochondria, where it is oxidized to acetyl-CoA and enters the citric acid cycle.
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Oxidative phosphorylation is the process by which NADH and FADH2 are oxidized and
oxygen is reduced. This process creates a proton gradient which is used to drive ATP
synthase and produce ATP. This process creates energy for cellular properties, and since
ATP is indispensable in the contraction process, so then, are mitochondria.
Mitochondrial enzymes, such as cytochrome c, succinate dehydrogenase, malate
dehydrogenase, α-ketoglutarate dehydrogenase, and citrate synthase, increase in
expression and activity in response to exercise (45). AICAR stimulation of AMPK
increases cytochrome c and δ-aminolevulinate synthase (ALAS), a rate-limiting enzyme
involved in the production of heme. Malate dehydrogenase and succinate dehydrogenase
also increase, as well as citrate synthase activity, in rats treated with AICAR injections
(46). Conversely, in LKB1 knockout mice, there are decreases in cytochrome c and
citrate synthase activity, even if the mice are “trained” by voluntary exercise (47).
Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) is a
transcriptional regulator for genes involved in mitochondrial biogenesis, fatty acid
oxidation, and gluconeogenesis (48). To do this, it enhances the activity of transcription
factors like nuclear respiratory factor 1 (NRF-1), myocyte enhancer factor 2 (MEF2),
host cell factor (HCF), and others (49, 50). It also has a positive feedback loop,
enhancing its own expression (51). Both MEF2 and cAMP response element (CRE) are
essential for contraction-induced PGC-1α promoter activity (50). AMPK is required for
increased PGC-1α expression in skeletal muscle in response to creatine depletion (52).
LKB1 knockout mice show a decrease in PGC-1α, as well as mitochondrial proteins
(47).
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Thyroid Hormone
Thyroid hormone is a tyrosine derivative synthesized in the thyroid. There are
two endogenous active forms of thyroid hormone, T3 and T4, and although T3 is the more
enzymatically active, T4 is the more prevalent in the body. T4 serves as a sort of
prohormone since it has a much longer half life in the blood, and it is readily converted
to T3 by deiodinases in the tissue. Thyroid hormone binds to a thyroid hormone receptor
bound to a thyroid hormone response element (TRE) on the target gene. This binding
facilitates transcription of the gene and subsequently an increase in target protein
expression (53).
Thyroid hormones regulate many processes involved in metabolism in the body.
They increase the rat of glucose uptake into muscle cells via increased GLUT4 transport
(54). Thyroid hormone has even been shown to ameliorate the hyperinsulinemia in
Zucker Diabetic Fatty (ZDF) rats by inducing GLUT4 protein expression in red and
white skeletal muscle (55). In the red skeletal muscle, the induction of GLUT4 is
transcriptional, whereas in white skeletal muscle, it seems to be due to a
posttranscriptional mechanism (55). A low affinity thyroid hormone receptor binding
site was found and characterized within the GLUT4 promoter gene, providing a possible
mechanism for direct stimulation of GLUT4 transcription by thyroid hormone (54).
Thyroid hormone also increases fatty acid oxidation and metabolism in skeletal
muscle (57). In hepatocytes it has been observed that thyroid hormone increases the
expression of PGC-1alpha and beta isoforms, and that both of these isoforms in turn
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increase thyroid hormone’s induction of CPT-1, acting as coactivators for thyroid
hormone (58, 59). Thyroid hormone also plays an important role in mitochondrial
biogenesis. Thyrotoxicosis induces increased expression of mitochondrial proteins, such
as citrate synthase, cytochrome c, cytochrome oxidase, α-glycerophosphate
dehydrogenase, and 3-hydroxybutyrate dehydrogenase, in skeletal muscle, especially the
soleus and red quad (60, 61).

Thyroid Hormone and AMPK
Just from the brief overview given in this paper, it is clear that AMPK and
thyroid hormone regulate some similar processes. Knowing these similarities, Winder
and Hardie et al designed an experiment to see if AMPK was influenced by thyroid
hormone (1). They found that all of the subunits of AMPK were increased in skeletal
muscle, especially in the soleus and red quadriceps, with thyroid hormone treatment.
There was also an increase in phospho-ACC, a marker of AMPK activity. At this point,
however, the AMPKK complex had not yet been characterized, so the method behind the
increase in AMPK activity remained unclear.

Proposal
AMPK and thyroid hormone share many similar metabolic effects, including
fatty acid oxidation, glucose uptake, and mitochondrial biogenesis. The subunits of
AMPK have also been shown to increase in response to thyroid hormone treatment, and
they decrease in the absence of thyroid hormone, providing evidence for a possible
regulatory role for thyroid hormone in AMPK-mediated pathways. There is also an
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increase in AMPK activity associated with thyroid hormone treatment. We will examine
whether or not the increase in AMPK activity is due to a thyroid hormone-induced
increase in LKB1, MO25, and STRAD. We hypothesize that LKB1, MO25, and STRAD
will increase in response to thyroid hormone treatment.
AMPK is activated by contraction, as has been said, and electrical stimulation of
muscle can simulate contraction and activate AMPK (62). Since it is known that AMPK
expression increases with thyroid hormone treatment, and since we hypothesize that
LKB1-STRAD-MO25 complex proteins will increase, it is logical to further hypothesize
that electrical stimulation of the muscle will cause an even greater increase in AMPK
activity in hyperthyroid rats. More substrate (AMPK) and more kinase (AMPKK) under
conditions of increased AMP/ATP ratio should result in more product formation.

Rat Treatment Protocol & Tissue Homogenization
All procedures are approved by the Institutional Animal Care and Use
Committee of Brigham Young University. 30 male Sprague-Dawley rats (Sasco,
Wilmington, MA) will be housed in a temperature controlled (21-22°C) room that cycles
daily with a 12-h light and 12-h dark period. Rats will be kept in individual, hanging
cages. Bedding will be replaced two times a week and all rats will be weighed every few
days to keep a log of rat growth rate. Rats will be divided into three treatment groups.
The first group (control) will receive powdered food and water ad libitum. The second
group will receive 0.01% proplythiouracil in their drinking water to inhibit thyroid
hormone synthesis. The third group will receive powdered Harlan Teklad rodent diet
containing 3 mg of thyroxine and 1 mg of 3,5,3’-triiodothyronine per kilogram for 4
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weeks. The night before we sacrifice the rats, they will receive the same amount of food,
which will be determined by their feeding habits. They will be anesthetized by sodium
pentobarbital injection (35-50 mg/kg ip). The soleus muscle, the gastrocnemius muscle,
the red and white regions of the vastus lateralis muscle, and the heart will be quickly
removed. Prior to removal of the left soleus and gastrocnemius muscle, the left tibial
nerve will be electrically stimulated for five minutes at 1/sec to activated AMPK. Once
removed, tissues will be compress frozen with metal tongs at liquid nitrogen temperature
(appx. -196°C), wrapped immediately in labeled aluminum foil and then placed in a
container filled with liquid nitrogen until they are stored later in an ultra-low temperature
(-90°C) freezer. All tissues will be ground with a mortar and pestle at liquid nitrogen
temperature and then homogenized in a homogenization buffer containing 250 mM
mannitol, 50 mM Tris-HCl, 50 mM NaF, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, and
1% triton all at a pH of 7.4. Just prior to homogenization 1 mM Dithiothreitol (DTT), 1
mM Benzamidine, 1μg/ml soybean trypsin inhibitor, and 0.5 mM AEBSF are added to
the buffer. The final concentration of the tissue in the homogenization buffer solution
will be a 9 factor dilution (1 g muscle powder / 9 ml buffer). Approximately 300 μl of
raw homogenate will be taken from the homogenate and the rest will then be centrifuged
at 1200 rpm for 20-m at 4°C. After the centrifugation, the supernatant from the
homogenate will be immediately taken from the tubes placed into 1500 μl Eppendorf
tubes.

Anticipated Experiments and Methods
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Western Blots - Blots will be run on homogenized soleus, red quadriceps, white
quadriceps, gastrocnemius, and heart of control, hyperthyroid, and hypothyroid rats to
test for LKB1, STRAD, MO25, and PGC-1. In the stimulated soleus and gastrocnemius,
we will blot for phospho-AMPK and phospho-ACC. These blots will enable us to see if
AMPKK complex protein changes in response to thyroid hormone treatment. The
phosphoproteins in the stimulated muscles will allow us to determine AMPK activation
and activity variations among the groups.

Western Blot Protocol - Samples (raw homogenate / supernatant) are mixed with 1 X
loading buffer that has been heated to 50°C for appx. 5-m. The samples are then loaded
into wells of an appropriate percent Tris-HCl, ready-made Criterion® gel. The proteins
in the sample are then separated via SDS-PAGE for 45-55 minutes at 200 V, depending
on the percent gel. Immediately after electrophoresis, gels are rinsed in Transfer Bx
(4°C) and properly placed in a protein transfer sandwich (fiber paper, filter paper, gel,
PVDF membrane, filter paper, fiber paper). Proteins will then be transferred to PVDF
membrane in mixing temperature controlled (4°C) Transfer Bx for 1-h at 100 V.
Blocking solution (1.25 non-fat dried milk / 25 ml PBST) is prepared (pH 7.6) while
transferring is taking place. Immediately following transfer, membranes are stained with
PONCEAU to confirm a successful transfer, washed and then allowed to incubate in
blocking solution for 1-h at rm. temperature. After blocking, the membrane is washed
for 30-m with PBST and PBS and then the membrane is incubated overnight with the
primary antibody at 4°C. The next day the membrane is washed for 30-m with PBST
and PBS and then allowed to incubate for one more hour with the correct secondary
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antibody with a Horseradish Peroxidase (HRP) tag. Immediately following incubation,
the membrane is washed one last time for 30-m with PBST and PBS. The membrane is
then exposed for 1 minute to a hydrolytic detecting solution (ECL) which will react with
HRP and produce light on the membrane. Last of all, the membrane is quickly exposed
to developing film in a dark room for the necessary time and the film is then developed,
revealing the blot pattern. All blots will be summarized on blot reports and significance
will be calculated.

Muscle Glycogen Assay- Glycogen is stored in both the liver and muscle tissue. The
liver has the highest concentration of glycogen, and it can break down the glycogen into
glucose, which can be passed into the blood stream for other tissues, especially the brain,
to use. Muscle cells do not have the ability to pass glucose directly into the blood
stream; they can break down glycogen for their own use, or they can convert it into
lactate and pass that into the blood for hepatic gluconeogenesis. The levels of glycogen
will indicate how much glycogen is stored in the treated rats. The likely decreased levels
of glycogen stores in hyperthyroid rats will confirm that the metabolic rate is increased,
and that more glycogen breakdown is needed for gluconeogenic substrates.

Muscle Glycogen Assay Protocol - Frozen tissue samples will be ground to powder
under liquid nitrogen with a mortar and pestle. 100 mg of ground tissue will be weighed
out and incubated for 30-m in 0.5 ml cold 30% KOH with a marble cap. After 30-m the
muscle mixture will be neutralized with 10.7 M acetic acid (~.55 ml). Once neutralized,
0.1 ml of mixture will be transferred to a 12 X 75 mm tube containing 0.9 ml
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amyloglucosidase buffer, capped and then incubated for 1-h at 55°C. Tubes are then
centrifuged for 10-m prior to 0.1 ml being transferred to a cuvette containing 0.88 ml
reaction buffer for an absorbance reading. Absorbance is read at an O.D. of 340 nm on a
spectrophotometer. 15-m after the first readings, a final absorbance reading is measured
with the addition of 0.02 ml G6PDH and HK enzyme mixture that has been mixed by
inversion. From the O.D. results we will then be able to calculate µmoles glucose (from
glycogen)/g tissue.

AMPK Activity Assay- The AMPK activity assay serves to test the hypothesis that the
increase is AMPK activity in hyperthyroid rats is due to an increase in the expression
and availability of LKB1, STRAD, and MO25. Since it is known that AMPK expression
is increased in hyperthyroid rats, and since we hypothesize that AMPKK will increase,
then there should be a greater increase in AMPK activity upon electrical stimulation.
The AMPK activity assay will allow us to measure that activity, and see the difference
between treatment groups.

AMPK Immunoprecipitation and Activity Assay Protocol - The two-step process of
the standard AMPK activity assay includes the immunoprecipitation of AMPK and then
the subsequent phosphorylation of SAMS peptide by phospho-AMPK. AMPK is
immunoprecipitated by incubating anti α2 AMPK antibody with Protein G-sepharose for
one hour. It is then resuspended in immunoprecipitation buffer (IP buffer). When the
sepharose/antibody mix is adequately resuspended and homogeneous, then 10 μl are
aliquotted into 1.5 ml Eppendorf tubes along with 50 μl of tissue homogenate. This
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mixture is incubated overnight to allow immunoprecipitation of AMPK. The next day,
the mixture is washed with IP buffer and salt to remove all nonspecific proteins. It is
then resuspended with 30 μl Hepes buffer. 10 μl are then pipetted into 12X75 test tubes.
We will be able to measure activity of the precipitated AMPK substrate through the
incorporation of a radioactive phosphate group (32P) from ATP into the SAMS peptide
serving as the AMPK substrate. 25 μl of phosphorylation buffer will be added to each
test tube, and the reaction will end by spotting 1-cm2 pieces of pre-cut P81 filter paper
(Whatman, Tewksbury, MA) with 15 ul of the final reaction mixture after 10-m.
Finally, the filter papers will be washed 6 times in 250 ml 1% phosphoric acid. The
phosphoric acid will be neutralized with Sodium Bicarbonate while the Whatman papers
are rinsed with acetone and allowed to dry. After the papers are dry they will be placed
in 3 ml of Ecolite (ICN, Irvine, CA) and then counted for 5 minutes on a scintillation
counter.

Buffers

Often DTT, Benzamidine, AEBSF and soybean trypsin inhibitor will be added to buffers
just prior to use in order to inhibit protease activity.
Muscle Homogenization Buffer: 250 mM mannitol, 50 mM Tris-HCl, 50
mM NaF, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1% triton pH adjusted to 7.4.
4 x Loading Buffer (92% stock soln.): 240 mM Tris-HCl, 8% SDS (sodium dodecyl
sulfate), 40% Glycerol, .04% bromophenol blue all at a pH of 6.8. Add 8% βmercaptoethanol just prior to use to bring the buffer to 100% stock solution.
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1 x Transfer Buffer (20% MeOH): 48 mM TRIS, 39 mM Glycine, .074% SDS, 20%
Methanol, pH 9.0.
100 mM Tris Buffer, pH 8.0: 4.02 grams Trizma HCl + 2.97 grams Trizma Base
diluted to 500 ml with distilled water. Adjust to final pH with HCl or KOH.
Amyloglucosidase buffer: (fresh daily - keep cold): Add 100 µg amyloglucosidase to 1
ml distilled water. Allow to dissolve. Add 0.1 ml from this solution to 10 ml, 50 mM
acetate buffer pH, 4.7.
Phosphorylation Buffer: 40 mM Hepes, 80 mM NaCl, 8% glycerol, 0.8 mM EDTA,
0.8 mM DTT, 5 mM MgCl2, 0.2 mM AMP, 0.2 mM ATP, 0.33 mM AMARA peptide,
0.05 μCi/μl [γ32]ATP, pH 7.0.
1 X Phosphate-buffered Saline (PBS): 138.6 mM NaCl, 2.71 mM KCl, 2.15 mM
KH2PO4, 9.89 mM Na2HPO4, pH 7.3.
1 X PBST: Same as PBS but add 0.1% Tween20.
IP Buffer: 50 mM Tris-HCl, 150 mM NaCl, 50 mM NaF, 5mM Na pyrophosphate, 1
mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM DTT, 1 mM benzamidine, 0.1 mM PMSF,
5 ug/ml soybean trypsin inhibitor, pH 7.4.
Hepes Buffer: 25 MM HEPES, 0.02% Brij, 1 mM DTT, pH 7.0.
Stock Solution: 100 mM HEPES, 200 mM NaCl, 20% glycerol, 2 mM EDTA, 12.5
mM MgCl2, pH 7.0.
Working Assay Cocktail: 0.5 mM AMP, 2 mM DTT, 0.5 mM ATP in stock solution. 1
mM SAMS peptide and 10 mCi/ml P32-ATP is added just before running the assay.
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Estimated Costs
The cost of analysis for the experiments should amount to approximately the
following values:
Western Blots•

Developing reagents ~ $4,000.

•

Antibodies net worth ~ $4,500.

Muscle Glycogen Assay ~ $100.
AMPK Activity Assay ~ $2000
•

P32-ATP ~ $300
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Abstract
AMP-activated protein kinase (AMPK), a heterotrimeric protein which serves as a
metabolic master switch in skeletal muscle, is a research target for the pharmaceutical
treatment and prevention of type 2 diabetes. The expression of all of the isoforms of the
subunits of AMPK and AMPK activity is increased in skeletal muscle tissue of
hyperthyroid rats. Activity of AMPK is regulated by an upstream kinase (AMPKK). The
LKB1-STRAD-MO25 complex is a major AMPKK in skeletal muscle. This experiment
was designed to determine whether the increase in AMPK activity is accompanied by a
thyroid hormone-induced increase in the expression of the LKB1-STRAD-MO25
complex. LKB1-STRAD-MO25 complex protein expression was determined by Western
blots in control rats, in rats given 3 mg of thyroxine and 1 mg of triiodothyronine per
kilogram chow for 4 weeks, and in rats given 0.01% propylthiouracil (PTU) in drinking
water for 4 weeks. The relative expression of LKB1, MO25, and STRAD, as well as
PGC-1α, increased in the soleus of thyroid hormone treated rats vs. the controls. MO25
mRNA increased with thyroid hormone treatment, and STRAD mRNA increased with
PTU treatment. Phospho-AMPK and phospho-ACC increased in response to electrical
stimulation in muscles of all treatment groups, but was most markedly increased in
hyperthyroid rats. Thyroid hormone treatment also increased the amount of phosphoCREB in the soleus, heart, and red quadriceps. These data provide evidence that thyroid
hormone partially controls expression of the LKB1-STRAD-MO25 complex, as well the
subsequent activation of AMPK.

Key Words: AMPK, LKB1, CREB, Acetyl-CoA carboyxlase, PGC-1α
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THESIS
Introduction
5’-AMP-activated protein kinase (AMPK) acts as a fuel gauge for the cell,
responding to changes in cellular energy (10, 41). When it “senses” low ATP, it turns off
ATP-depleting pathways and switches on mechanisms of ATP production (10, 41).
AMPK is a heterotrimer consisting of a 63-kD alpha subunit, a beta subunit, and a
gamma subunit (11). There are at least two isoforms each of the alpha and beta subunits,
and three isoforms of the gamma subunit (10, 41). AMPK is activated during exercise,
ischemia, and hypoxia, and other forms of cellular stress (31). AMPK senses increases in
the AMP/ATP ratio and the creatine/creatine phosphate (CP) ratio (31). AMPK is
allosterically activated by AMP, and inhibited by ATP (10, 39), which allows for its
sensitivity to cellular energy. ATP inhibits AMPK by binding to the Bateman domains
on the gamma subunit (10). AMP is reported to activate AMPK via three distinct
pathways. The first pathway involves allosteric activation of AMP via binding to the
gamma subunit (10, 13). AMP, when bound to the gamma subunit, also makes AMPK a
poor substrate for protein phosphatase 2C (30, 39). The third pathway, that AMPbinding makes AMPK a better substrate for AMPK kinase (AMPKK) is currently in
dispute (14, 30, 34, 45).
LKB1, STE20-related adaptor protein (STRAD), and mouse protein 25 (MO25)
form a complex which makes up the upstream kinase for AMPK, with LKB1 in
possession of the catalytic domain (2, 3, 12). LKB1 is a serine/threonine kinase, which
has been shown to be a tumor suppressor (2, 3, 12, 38). Mutations in LKB1 are linked to
Peutz-Jeghers syndrome, in which multiple gastrointestinal polyps form and the
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likelihood of malignant tumors is greatly increased (2, 16). LKB1 alone is mainly
localized in the nucleus, but when associated with STRAD and MO25, it is anchored in
the cytoplasm (2, 3). STRAD and MO25 have no catalytic function (3). Association
between LKB1 and STRAD is enhanced by increasing levels of MO25 in a dosedependent fashion. Optimal activation of AMPK by LKB1 requires the presence of all
three proteins (2, 3, 12).
Aware of the similarities between the effects of thyroid hormone and those of
AMPK, Park et al. (27) designed an experiment to see if AMPK was influenced by
thyroid hormone. They found that all of the subunits of AMPK were increased in
skeletal muscle, especially in the soleus and red quadriceps, with thyroid hormone
treatment. There was also an increase in both acetyl-CoA carboxylase (ACC) and
phospho-ACC. Malonyl-CoA concentration was reduced in thyroid hormone treated rats.
At this point, however, the AMPKK complex had not yet been characterized, so the
mechanism of the increase in AMPK activity remained unclear. In an effort to see the
effect of thyroid hormone upon these AMPKK complex proteins, which are now
characterized, we designed an experiment similar to that of Park et al. (27),
hypothesizing that, just as the AMPK protein subunit expression increased with thyroid
hormone treatment, so too, would the expression of LKB1, STRAD, and MO25.
Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) is a
transcriptional regulator for genes involved in mitochondrial biogenesis, fatty acid
oxidation, and gluconeogenesis (28). PGC-1α enhances the activity of transcription
factors like nuclear respiratory factor 1 (NRF-1), myocyte enhancer factor 2 (MEF2),
host cell factor (HCF), and others (1, 24). It also has a positive feedback loop, enhancing
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its own expression (8). Both a MEF2 site and cAMP response element (CRE) are
essential for contraction-induced PGC-1α promoter activity (1). AMPK is required for
increased PGC-1α expression in skeletal muscle in response to creatine depletion (47).
LKB1 knockout mice show a decrease in PGC-1α, as well as mitochondrial proteins
(37). Irrcher et al. (19) found that PGC-1α expression increased in skeletal muscle after
5 days of thyroid hormone treatment, the largest increase occurring in the soleus.
Cyclic AMP response element binding protein (CREB) is a well-characterized
transcription factor activated by various stimuli (33). It was originally discovered as a
downstream target of the cAMP pathway. CREB is activated by phosphorylation at the
serine 133 position (6, 9). CREB is involved in a variety of cellular processes such as
proliferation, development, and differentiation. It is also involved in metabolic
processes, such as regulation of gluconeogenesis by glucagon and epinephrine (9, 33).
Mendez-Pertuz et al. (23) found that treatment with thyroid hormone will decrease the
phosphorylation of CREB by PKA at the serine 133 position in pituitary cells. On the
other hand, Ghosh et al. (5) reported that thyroid hormone influences the differentiation
and maturation of astrocytes via activation of the PKA pathway. Due to recent
experiments in our lab (W. Winder, unpublished data), showing that AMPK and PKA
both phosphorylate CREB at the serine 133 position, and knowing that PGC-1α, whose
gene sequence contains a CRE, increases in thyroid hormone-treated rats, we
hypothesized that CREB phosphorylation would increase in skeletal muscle upon
treatment with thyroid hormone (19, 22).
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Materials and Methods:
Animal care. All procedures were approved by the Institutional Animal Care and Use
Committee of Brigham Young University. Male Sprague-Dawley rats (Sasco,
Wilmington, MA) were housed in individual cages in a room lighted from 6 AM to
6 PM. Rats were fed powdered Harlan Teklad rodent diet (Madison, WI). Rats weighed
an average of 107 ± 20.6 g at the beginning of treatments. Rats were divided into three
treatment groups. The first group (controls) received powdered food and water ad
libitum. The second group received 0.01% propylthiouracil (PTU) in drinking water for
4 wk for the purpose of inhibiting thyroid hormone synthesis. The third group was
provided with powdered Harlan Teklad rodent diet containing 3 mg of thyroxine and
1 mg of 3,5,3'-triiodothyronine per kilogram for 4 wk. On the afternoon before the rats
were killed, they were given 20 g of rat chow.

Muscle stimulation, collection, and homogenization. Rats were anesthetized with
pentobarbital sodium (0.08 mg/g body wt) for at least 30 min before beginning the
procedure. The right soleus and gastrocnemius were isolated and frozen using aluminum
block tongs at liquid nitrogen temperature. The left tibial nerve was isolated and
stimulated at a frequency of 1/s, 10-ms duration, 15 volts, for 5 min. The left
gastrocnemius and soleus were then removed and clamp-frozen. The red and white
quadriceps, heart, and liver were also removed at this time. Tissues were kept frozen at
95°C until analyses. The retroperitoneal fat pads were weighed as an indicator of
adiposity. Muscles were weighed and then homogenized in 9 vol of homogenization
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buffer (50 mM Tris·HCl, 250 mM mannitol, 50 mM NaF, 5 mM sodium pyrophosphate,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM benzamidine, 0.1 mM
phenylmethanesulfonyl fluoride, and 5 µg/ml soybean trypsin inhibitor; pH 7.4). The
homogenate was centrifuged at 1,200 g and 4°C, and the supernatant was kept for
analysis.
Western blotting and immunodetection. Homogenates were diluted in sample loading
buffer (50 mM Tris·HCl, pH 6.8, 10% glycerol, 2% SDS, 2% -mercaptoethanol, and
0.1% bromphenol blue) and loaded (4 µl homogenate) on 5% [phospho (p)-ACC,PGC1], 7.5% (p-AMPK, PGC-1, LKB1), or 10% (pCREB, CREB, MO25, STRAD) Tris·HCl
gels (Bio-Rad Criterion System, Hercules, CA.). Electrophoresis was applied for 53 min
at 200 volts, after which the proteins were transferred to polyvinylidene difluoride
membranes at 100 volts for 1 h. Membranes were stained with Ponceau S to ensure even
transfer and protein loading across lanes then washed in Tris-buffered saline plus Tween
(TBST), blocked for 1 h at room temperature in 5% nonfat dry milk in TBST, and
probed overnight at 4°C with primary antibody diluted in 1% BSA dissolved in TBST.
Commercially available antibodies and dilutions were as follows: LKB1, p-ACC and pAMPK (1:1000, 1:750 and 1:1000 resp.; Cell Signaling Technology, Beverly, MA);
STRAD and MO25 (1:20,000; Affinity Bioreagents, Inc, Golden, CO); CREB and PGC1 (1:5000 and 1:1,000; Chemicon International, Temecula, CA); and p-CREB (1:2000;
Upstate, Lake Placid, NY). After primary antibody incubation, the membranes were
washed in TBST and incubated for 1 h at room temperature in HRP-conjugated
secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted in
1% nonfat dry milk in TBST. Membranes were again washed in TBST and then covered
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with enhanced chemiluminescence Western blotting detection reagent (GE Healthcare
Biosciences Corp) for 1 min. HRP activity was then detected using autoradiographic film
(Classic Blue Sensitive; Midwest Scientific, St. Louis, MO). Relative band intensity was
quantified using the Spot Denso function of AlphaEaseFC software (Alpha Innotech, San
Leandro, CA).
Real-time PCR. Relative changes in mRNA with training were examined by real-time
PCR. Total mRNA was isolated from 20-30 mg of tissue from control, thyroid hormone
treated rats, and PTU treated rats with the RNeasy fibrous tissue kit (Qiagen) according
to the manufacturer's instructions. Samples were homogenized with an Ultra-Turrax T8
(IKA, Wilmington, NC). cDNA libraries for each sample were generated using the
SuperScript III first-strand synthesis kit (Invitrogen) according to the manufacturer's
instructions. Real-time PCR using gene-specific primers for LKB1, MO25, and STRAD
mRNA and 18S rRNA was performed, using the Platinum SYBR Green qPCR Supermix
UDG kit (Invitrogen) with an ABI-7000 real-time PCR System. Primers (Invitrogen)
were the following: LKB1 forward, AGAGGAAGTGGGTCAGAATGGA; LKB1
reverse, CCGGCCTTCTGGCTTCA; MO25 forward,
GGTTGCCATGAAAGAAATTCTGT; MO25 reverse,
AGCTGTGCTACGGCCTCTGT; STRAD forward, TCCGAGGCTTTACCTGAGTTG;
STRAD reverse, AGACTGGCTGCCCTCGAA; 18S forward,
GTGCATGGCCGTTCTTAGTTG; and 18S reverse,
GCCACTTGTCCCTCTAAGAAGTTG. Samples were amplified in triplicate.
Amplification protocol was 50°C for 2 min and 95°C for 10 min and then 60 cycles of
95°C for 15 s, 60°C for 20 s, and 72°C for 30 s. For postamplification dissociation to
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generate melting curves, temperature was raised from 60°C to 95°C. Cycle threshold
(CT) was calculated automatically by the ABI software. Relative fold expression was
calculated using the 2–

CT

method after normalizing to 18S RNA (21).

Results
Evidence of hyper- and hypothyroid conditions.
The final body weights for the control, thyroid, and PTU were 283 ± 11, 249 ±
12, and 228 ± 8 g respectively. Final body weights for both thyroid and PTU rats were
significantly less than the control (P < 0.05). As evidence that the PTU was indeed
inhibiting thyroid hormone production, there was marked hypertrophy of the thyroid in
PTU treated rats (71.0 ± 8.6 mg vs. 19.0 ± 2.2 mg in controls). The retroperitoneal fat
pad weight expressed as a percentage of body weight for the control, thyroid, and PTU
were 0.58 ± 0.04, 0.08 ± 0.01, and 0.39 ± 0.03, respectively. The fatpad weight for
thyroid and PTU rats were both significantly less than the control, and the thyroid rats
were significantly less than both controls and PTU rats (P < 0.05). The heart weights for
the control, thyroid, and PTU rats were 0.79 ± 0.02, 1.36 ± 0.07, 0.58 ± 0.02 g
respectively. The thyroid and PTU heart weights were significantly different from
controls (P < 0.05). Expressed as a percentage of body weight, the heart weights for the
three groups were, respectively, 0.28 ± 0.01, 0.55 ± 0.02, and 0.25 ± 0.01 with the
thyroid group being significantly different from both (P < 0.05). During the last week
before the animals were sacrificed, the average daily food intake for control, thyroid, and
PTU was 30.7 ± 0.4, 40.0 ± 1.3, and 22.9 ± 1.1 g respectively. Both thyroid and PTU
groups were significantly different from controls.
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LKB1, STRAD, and MO25 Western Blot in skeletal muscle
LKB1, STRAD, and MO25 migrated in the gel to the approximate positions
based on their molecular weight (LKB1 at 55 kD, STRAD at 48 kD, and MO25 at 40
kD). Figure 1A-C shows that all LKB1, STRAD, and MO25 were present in
significantly higher amounts (150%, 200%, and 160% increases respectively compared
to the control) in the thyroid rats than in control rats in soleus muscle (P < 0.05). In
heart, red quad, white quad, and gastrocnemius muscle, MO25 expression increased
approximately 140%, 150%, 125%, and 210% respectively in the thyroid hormone
treated rats (P < 0.05). LKB1 and STRAD expression varied among the different muscle
types (see Table 1).

Phospho-ACC and phospho-AMPK Western Blot in resting and stimulated skeletal
muscle.
A previous study showed that both ACC and phospho-ACC increase in skeletal
muscle due to thyroid hormone treatment (12). To test whether thyroid hormone
treatment would increase the amount of AMPK phosphorylation as well as activation, as
shown by the subsequent phosphorylation of ACC, we stimulated the left tibial nerve for
5 minutes. Both gastrocnemius and soleus muscles showed an increase in phosphoAMPK under resting conditions (see Fig 2). Figure 3 shows that, upon stimulation, the
relative phosphorylation of ACC increased approximately 60% more in the
gastrocnemius of thyroid hormone treated rats (increase compared to the average resting
control rat phospho-ACC levels), than in the control rats. The relative amount of
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phospho-AMPK did not increase significantly in the gastrocnemius of thyroid hormone
treated rats, but there was a trend to increase (data not shown). Also, when the amount of
phospho-AMPK was compared only in the stimulated gastrocnemius, there was 70%
more phospho-AMPK in thyroid hormone treated rats than in the PTU rats and 45%
more phospho-AMPK than in the control rats, although the difference from the control
rat tissue was not significant. The phospho-ACC level in the stimulated gastrocnemius of
thyroid hormone treated rats was about 60% higher than in the stimulated gastrocnemius
of control rats.

CREB and PGC-1α Western Blot in skeletal muscle
CREB protein expression decreased by 20% in heart muscle in PTU rats
compared to the other groups. CREB did not change among the treatment groups for the
other muscle types (see Table 2). Figure 4 shows that PGC-1α expression was 40%
higher in the soleus of thyroid hormone treated rats than that of the control rats (P <
0.05). There was no significant change in any of the other muscle types (data not
shown).

Phospho-CREB Western Blot in resting and stimulated muscle
Under resting conditions, phospho-CREB levels were significantly higher in
thyroid hormone treated rats in the soleus, heart, and red quadriceps (120%, 70%, and
40% higher than control respectively) than in the control rats (see Fig 5). There was a
trend to increase in the gastrocnemius, but the increase was not significant. Upon
electrical stimulation, however, there is a two-fold increase in CREB phosphorylation in
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the gastrocnemius of the thyroid hormone treated rats. In control and PTU treated rats,
there is no significant increase in phospho-CREB upon stimulation (see Fig 5D).

LKB1, STRAD, and MO25 mRNA expression
Relative levels of LKB1, STRAD, and MO25 mRNA were measured in the
soleus of control, PTU, and thyroid hormone treated rats. LKB1 mRNA levels did not
change with thyroid hormone or PTU treatment. MO25 mRNA increased approximately
to 170% of the control with thyroid hormone treatment. STRAD mRNA did not increase
with thyroid hormone treatment, but, surprisingly, it increased to about 150% of the
control with PTU treatment (see Fig 6).

Discussion
A previous study from this lab (27) showed that AMPK is regulated, at least in
part, by thyroid hormone. All isoforms of the subunits of AMPK were influenced by
thyroid hormone and PTU treatment. There was also a decrease in malonyl-CoA content
in muscles of thyroid hormone treated rats. ACC and phospho-ACC increased in
response to thyroid hormone treatment, and the phosphorylation of ACC corresponded
to the amount of ACC. Due to the changes in malonyl-CoA and ACC activity, it seemed
that thyroid hormone could regulate the activity, as well as the amount, of AMPK.
The AMPKK complex proteins were not characterized until 2003 (3, 12), and it
was therefore impossible at the time of Park’s (27) study to determine the effect of
thyroid hormone on LKB1, STRAD, and MO25. It seemed likely that the expression of
these proteins would increase in response to thyroid hormone treatment just as the
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subunits of AMPK had. This proved to be the case, although the increase in LKB1,
STRAD, and MO25 seemed more tissue dependent than the changes in AMPK subunit
expression. LKB1, STRAD, and MO25 all increased significantly in the soleus of
thyroid hormone treated rats. MO25 increased significantly in all other tissue types
analyzed – heart, gastrocnemius, red quadriceps, and white quadriceps.
The mechanism by which LKB1, STRAD, and MO25 expression increased in
this study is unknown. Since thyroid hormone generally elicits a cellular response by
means of binding to a receptor in the nucleus, it would seem likely that thyroid hormone
would increase transcription of the genes which encode for LKB1, STRAD, and MO25.
It seems that this is not necessarily the case. MO25 mRNA increased to 170% of control
levels in response to thyroid hormone treatment, following the trend observed by
Western Blot, but LKB1 and STRAD did not increase significantly. STRAD mRNA did
increase to 150% of control levels, however, in the soleus of the PTU treated rat.
In order to further delineate the mechanism by which thyroid hormone regulates
the increase in MO25 mRNA, and by which the lack of thyroid hormone increases
STRAD mRNA, we looked for possible thyroid hormone response elements in promoter
regions for the genes encoding for these proteins. We found a possible, although weak,
thyroid hormone response element (TRE) in human chromosome 19 on the possible
promoter region for the STK11 gene proposed by Hearle et al. (7, 15). It consists of a
single AGGTCA sequence, so its ability to function is questionable (NCBI Accession #
AC011544). We also saw a potential TRE (GGATCACCTGAGGTCA) about 1500 kb
upstream of the start sequence for STRAD on the LYK5 gene (NCBI Accession #
AC015651). We did not find a TRE sequence upstream of the gene encoding for MO25
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(NCBI Accession # AC084031). It is possible, therefore, that thyroid hormone binds to
the TRE’s we located to regulate the increase in expression of LKB1, STRAD, and
MO25, but, since no definitely functional TRE was found for these genes, it is more
probable that thyroid hormone regulates the transcription of genes which encode for
other transcriptional regulators, coactivators, or corepressors.
It is interesting that MO25 mRNA was the only one of the three analyzed that
increased, although the protein expression for all three increased in the soleus of thyroid
hormone treated rats. We observed similar results in our lab in a study on endurance
training, when we analyzed the red quadriceps of trained rat (36). LKB1 and MO25
protein expression increased, but only MO25 mRNA expression increased. So although
the increase in MO25 mRNA observed in our current study may in part be responsible
for the increase in MO25 protein expression, the mRNA for LKB1 and STRAD do not
seem to be responsible for the increase in protein expression. It was suggested in our
previous study (36) that LKB1 may increase due to protein-protein interactions, such as
binding to HSP90 (4, 26), since HSP90 has been shown to increase LKB1 protein
expression. It is unknown why STRAD mRNA increases in PTU treated rats, while the
protein expression tends to decrease. It is possible that STRAD mRNA is quickly
destabilized, so that only a smaller portion of it is translated into protein.
The left tibial nerve was stimulated for five minutes prior to removal in order to
activate AMPK in the gastrocnemius (18). Since we hypothesized that LKB1, STRAD,
and MO25 would increase in response to thyroid hormone treatment, and knowing from
Park’s study (27) that AMPK expression increases in response to thyroid hormone, it
followed that upon electrical stimulation there would be a greater activation of AMPK
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and subsequent phosphorylation of ACC. There was a greater increase in ACC
phosphorylation upon stimulation in the thyroid hormone treated rat gastrocnemius,
indicating that there was more AMPK activity. There was a higher content of
phosphorylated AMPK in the stimulated muscle of thyroid hormone treated rats,
although the relative phosphorylation (amount of phospho-AMPK in stimulated
gastrocnemius compared to the resting control) did not significantly increase. It appears
that thyroid hormone treatment results in increased phosphorylation and activation of
AMPK, and when the muscle is electrically stimulated, there is a great amount of AMPK
activation in thyroid hormone treated rats. The total amount of phosphorylated AMPK
increases simply because there is more enzyme (LKB1, STRAD, MO25) and more
substrate (AMPK). It seems logical, therefore, under conditions where AMPK can be
activated, such as electrical stimulation, that if there is more AMPKK present and more
AMPK, then there will be an increased amount of phospho-AMPK.
It is also interesting that an increase in phospho-AMPK was observed in the
gastrocnemius, even though MO25 was the only AMPKK complex protein whose
expression increased. It seems that MO25 is the most highly influenced by thyroid
hormone treatment out of the three AMPKK complex proteins (there was a significant
increase in expression in all tissue types analyzed). It is possible, therefore, that MO25 is
responsible, at least in part, for the increase in AMPK activity observed upon treatment
with thyroid hormone. This is further supported by the fact that MO25 was the only
AMPKK complex protein showing increased expression increased in the gastrocnemius
of thyroid hormone treated rats, yet an increase in AMPK activity was still observed in
the gastrocnemius.
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CREB is a transcription factor involved in numerous cellular and metabolic
processes. It binds to cyclic AMP response element (CRE), where it can be activated by
phosphorylation at the serine 133 position (20). This phosphorylation allows for
recruitment of CREB binding protein (CBP) or p300, two similar proteins that have
histone acetylase activity (HAT), as well as the ability to interact with basal transcription
factors such as TFIIB and TATA-binding protein (TFB) (20, 32). There are CRE’s on
many different genes involved in cell proliferation, differentiation, and division, as well
as metabolic regulations, and when CREB is activated, it can facilitate the transcription
of these genes (25, 32, 33, 35). We observed an increase in phospho-CREB in the soleus,
heart, and red quadriceps of thyroid hormone treated rats. Since the amount of CREB
protein did not change due to thyroid state, except for a decrease in expression in the
heart of PTU treated rats, it is evident that thyroid hormone treatment increases the
amount of phosphorylation of CREB, and possibly its activation. This could occur
through various different pathways, since CREB can be phosphorylated by a variety of
proteins. The best known pathway is through PKA, but it is dependent on cAMP
concentration, and cAMP levels have been shown to decrease in the soleus during
thyrotoxicosis, it seems unlikely that this increase is PKA mediated (40). Another
interesting observation was that phospho-CREB increases in the gastrocnemius upon
electrical stimulation only in the thyroid hormone treated rats (see Fig 6D). It is possible
that thyroid hormone prepares the muscle cell to quickly activate CREB upon muscle
contraction.
It was not surprising to observe an increase in PGC-1α in soleus muscle of
thyroid hormone treated rats. It simply confirmed what Irrcher et al. (19) found in their
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study. It is also known that CREB induces expression of PGC-1α, at least in the liver
(17). Since we observed that thyroid hormone treatment increased AMPK activity, as
well as CREB phosphorylation, the increase in PGC-1α followed the trend. It was
interesting to note, however, that although phospho-AMPK and phospho-CREB
increased in various tissue types upon treatment with thyroid hormone, PGC-1α only
increased in the soleus. The soleus muscle seems to be the muscle tissue type most
heavily influenced by thyroid hormone, so it is unsurprising that an increase in protein
expression would be seen there and not elsewhere (40, 43).
It is possible that the increase in LKB1, and subsequent activation of AMPK, by
thyroid hormone could be partially responsible for some of thyroid hormone’s effects on
metabolism. Hyperthyroidism results in marked increases in glucose uptake, fatty acid
oxidation, and oxidative capacity. The induction of PGC-1α has been shown in
hepatocytes to increase, among other things, the induction of carnitine
palmitoyltransferase-1 (CPT-1) which aids in the transport of fatty acids into the
mitochondrion for oxidation (29, 46). AMPK has been shown to relieve the inhibition of
CPT-1 by malonyl-CoA by inactivating ACC (42), so it seems possible that the increase
in fatty acid oxidation observed in hyperthyroid patients occurs by increasing expression
of LKB1, STRAD, and MO25, which leads to subsequent AMPK activation, as well as
by increasing expression of PGC-1α.
Another effect of hyperthyroidism is increased oxidative capacity. It has been
shown that thyrotoxicosis induces increased expression of mitochondrial proteins, such
as citrate synthase, cytochrome c, cytochrome oxidase, α-glycerophosphate
dehydrogenase, and 3-hydroxybutyrate dehydrogenase, in skeletal muscle, especially the
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soleus and red quad (40, 43). AICAR stimulation of AMPK increases cytochrome c and
δ-aminolevulinate synthase (ALAS), a rate-limiting enzyme involved in the production
of heme. Malate dehydrogenase and succinate dehydrogenase also increase, as well as
citrate synthase activity, in rats treated with AICAR injections (44). Conversely, in
LKB1 knockout mice, there are decreases in cytochrome c and citrate synthase activity,
even if the mice are “trained” by voluntary exercise (37). It is therefore conceivable that
thyroid hormone-induced increases in LKB1-STRAD-MO25 complex proteins, and the
ensuing activation of AMPK, are partially responsible for the thyrotoxic increase in
oxidative capacity.
In conclusion, we found that thyroid hormone treatment does increase the protein
expression of LKB1, STRAD, and MO25, as well as the activity of AMPK upon
electrical stimulation. Thyroid hormone treatment also increases the phosphorylation of
CREB in the soleus. These results suggest that thyroid plays at least some role in the
regulation of AMPK activity and the activation of CREB in skeletal muscle.
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Figure Legends
Figure 1
Relative expression of A) LKB1, B) STRAD, and C) MO25 in control (cntrl), thyroid
hormone-treated (hyper) and PTU-treated rats (hypo). LKB1 expression in hyper- and
hypothyroid rats was significantly different from the control. STRAD and MO25
expression in hyperthyroid rats was significantly higher than in the controls (n=9, p <
0.05, * = significantly different from the control).

Figure 2
Activation of AMPK was measured by western blot showing relative quantities of
phosphothreonine-172 AMPK (pAMPK) in A) resting gastrocnemius and B) resting
soleus. There was significantly more phospho-AMPK in the hyperthyroid rats than the
control for both gastrocnemius and soleus. There was significantly less phospho-AMPK
in the soleus of the hypothyroid rats than the control, but there was no significant
difference in the gastrocnemius (n=9, p < 0.05, * = significantly different from the
control).

Figure 3
Activity of AMPK was determined by measuring the phosphorylation of ACC in
stimulated muscle by western blot. 3A shows the amount of phospho-ACC in the
stimulated muscle relative to the amount of phospho-ACC in the resting control.
Phospho-ACC increases significantly in the stimulated gastrocnemius of all three
treatment groups relative to the control, but the hyperthyroid rats have the most
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markedly increased amount of phospho-ACC. 3B shows the relative amount of phosphoAMPK in the stimulated gastrocnemius (n=9, p < 0.05, * = significantly different from
the control).

Figure 4
Relative expression of PGC-1α in control, hyper-, and hypothyroid rats was determined
by western blot. Expression of PGC-1α in the soleus of hyperthyroid rats was
significantly higher than the control (n=9, p < 0.05, * = significantly different from the
control).

Figure 5
Activation of CREB was determined by western blot in control, hyper-, and hypothyroid
rats showing relative expression of phosphoserine-133 CREB (pCREB) in resting A)
soleus, B) heart, and C) red quadriceps. Phospho-CREB increased significantly in all
three muscle types vs. the control. Phospho-CREB decreased significantly in the soleus
and heart of hyperthyroid rats, but not in the red quadriceps. 5D shows the amount of
phospo-CREB in the stimulated muscle relative to the amount of phospho-CREB in the
resting control. Phospho-CREB increases significantly in the stimulated gastrocnemius
only in the hyperthyroid rats (n=9, p < 0.05, * = significantly different from the control).

Figure 6
Relative amounts of mRNA in the soleus of control, hyper-, and hypothyroid rats for A)
LKB1, B) STRAD, and C) MO25 were determined by real-time PCR. MO25 mRNA
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increased significantly in hyperthyroid rats, whereas STRAD increased significantly in
hypothyroid rats. There was no significant change in LKB1 mRNA (n=8, p < 0.05, * =
significantly different from the control).
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Figure 1.
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Figure 2.
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Figure 3.
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Figure 5.
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Figure 6.
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MO25 mRNA (% control)
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Table 1. LKB1, STRAD, and MO25 protein expression in heart and skeletal
muscle.
AMPKK Complex Proteins
LKB1
STRAD
Red Quadriceps
Control
PTU
T3&4

100
77±6 *
94±4

100
103±3
103±6

Control
PTU
T3&4

100
118±8
132±11 *

Control
PTU
T3&4

100
118±7
125±12

Control
PTU
T3&4

100
95±4
100±4

MO25
100
80± 11
148±12 *,°

White Quadriceps
100
96±3
107±5 °

100
90±5
124±10 *,°

100
101±5
102±6

100
120±27
208±32 *

100
105±12
82±11

100
64±9 *
140±17 *,°

Gastrocnemius

Heart

Values are means ± SE (n =9). PTU, propylthiouracil; T3&4, thyroid hormone treatment for 4 wk.
* P < 0.05 vs. control. ° P < 0.05 vs. PTU.
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